Skip to main content
. 2021 Mar 5;11(3):e044971. doi: 10.1136/bmjopen-2020-044971

Table 1.

PRISMA-P 2015 checklist

Section and topic Item no. Checklist item Information reported Page number
Administrative information
Title:
 Identification 1a Identify the report as a protocol of a systematic review. Yes 1
 Update 1b If the protocol is for an update of a previous systematic review, identify as such. Not applicable
Registration 2 If registered, provide the name of the registry (such as PROSPERO) and registration number. Yes 2, 4
Authors:
 Contact 3a Provide name, institutional affiliation, email address of all protocol authors; provide physical mailing address of corresponding author. Yes 1
 Contributions 3b Describe contributions of protocol authors and identify the guarantor of the review. Yes 8
Amendments 4 If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments. Not applicable
Support:
 Sources 5a Indicate sources of financial or other support for the review. Not applicable
 Sponsor 5b Provide name for the review funder and/or sponsor. Not applicable
 Role of sponsor or funder 5c Describe roles of funder(s), sponsor(s) and/or institution(s), if any, in developing the protocol. Not applicable
Introduction
Rationale 6 Describe the rationale for the review in the context of what is already known. Yes 4
Objectives 7 Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators and outcomes (PICO). Yes 4
Methods
Eligibility criteria 8 Specify the study characteristics (such as PICO, study design, setting and time frame) and report characteristics (such as years considered, language and publication status) to be used as criteria for eligibility for the review. Yes 5–6
Information sources 9 Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage. Yes 6
Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated. Yes 6 and table 3
Study records:
 Data management 11a Describe the mechanism(s) that will be used to manage records and data throughout the review. Yes 6–7
 Selection process 11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (ie, screening, eligibility and inclusion in meta-analysis). Yes 6–7
 Data collection process 11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators. Yes 6–7
Data items 12 List and define all variables for which data will be sought (such as PICO items and funding sources), any preplanned data assumptions and simplifications. Yes 5–6
Outcomes and prioritisation 13 List and define all outcomes for which data will be sought, including prioritisation of main and additional outcomes, with rationale. Yes 6
Risk of bias in individual studies 14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis. Yes 7
Data synthesis 15a Describe criteria under which study data will be quantitatively synthesised. Yes 7
15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I2, Kendall’s τ). Yes 7
15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression). Yes 7
15d If quantitative synthesis is not appropriate, describe the type of summary planned. Yes 7
Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies and selective reporting within studies). Not applicable
Confidence in cumulative evidence 17 Describe how the strength of the body of evidence will be assessed (such as GRADE). Yes 7

GRADE, grades of recommendations assessment, development and evaluation; PRISMA-P, Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols.